4th Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$660,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Part A, B and D AMP Cap H.R 3 S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1046/S.377 - Medicare Negotiation and Competitive Licensing Act of 2019 Innovative pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Drug Pricing Outcomes Based Contracts/value based arrangements Medicaid H.R.275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R.448 - Medicare Drug Price Negotiation Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.107 - To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R.4455 - BIOSIM Act H.R.4619 - Pharmaceutical Rebates for Excessive Pricing Above Inflation Act HR. 3772 - The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 HR. 4597 - Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 S.3466 - ACCESS for Biosimilars Act of 2020 HR. 6179 - Increasing Access to Biosimilars Act of 2020 HR. 4629 - Star Rating for Biosimilars Act S. 3129 - Lower Costs, More Cures Act of 2019 S. 3384 - Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 S. 3457 - Preserving Patient Access to Home Infusion Act H.R.5741 - Strengthening Innovation in Medicare and Medicaid Act Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Transparency policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08) Proposed Rule; Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans (CMS-9916-P) Reimbursement for cell therapy products S. 3353/H.R. 5534 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act Patient Cost-Sharing and Smoothing S. 4134 - Increasing Access to Biosimilars Act of 2020 S. 102 - Prescription Drug Price Relief Act of 2019 CMS Proposed Rule: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) or Drugs Covered in Medicaid, Revising Medicaid Rebate and Third Party Liability (TPL) Requirements (CMS-2482-P) H.R. 8624 - Protecting Access to Innovation During COVID-19 Act H.R. 8702 - Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020 S. 1895 - Lower Health Care Costs Act S. 4199 - Prescription Drug Pricing Reduction Act of 2020 S. 4274 - Legalizing Drug Discounts for Seniors Act of 2020 Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid rebates and waiver policy issues Medicare prescription drug payments cards and related issues ASP reporting policy issues Non-covered drugs policy issues Drug wastage rebates policy issues

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON New —

Contacted: Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); White House Office; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Commerce, Dept of (DOC); SENATE

Bills named: H.R. 5534 (116th), S. 4199 (116th), S. 3466 (116th), H.R. 8702 (116th), H.R. 275 (116th), S. 377 (116th), S. 3129 (116th), H.R. 1046 (116th), H.R. 19 (116th), S. 4134 (116th), S. 3353 (116th), H.R. 8624 (116th), H.R. 448 (116th), H.R. 3 (116th), S. 102 (116th), S. 3457 (116th), S. 2543 (116th), S. 3384 (116th), S. 1895 (116th), H.R. 4629 (116th), H.R. 6179 (116th), H.R. 4455 (116th), H.R. 107 (116th), H.R. 4619 (116th), H.R. 4597 (116th), S. 4274 (116th), H.R. 5741 (116th), H.R. 3772 (116th)

Science/Technology SCI

Artificial intelligence Data and digital technologies

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
SHELLY MUI-LIPNIK —

Contacted: White House Office; Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE; U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); State, Dept of (DOS); U.S. Trade Representative (USTR); Office of Management & Budget (OMB)

Veterans VET

Health care collaboration opportunities

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); State, Dept of (DOS); Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); SENATE; Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA)

Trade (domestic/foreign) TRD

Free Trade Agreements - Intellectual Property and Transparency Provisions - Free Trade Agreements China Agreement UK Agreement Intellectual Property Access to Medicines Issues Global Health Issues India, China and Canada IP and Market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Regulatory Cooperation USTR Special 301 Report/National Trade Estimate Trade Policy Tariffs CFIUS USMCA Pharmaceutical supply chain H.R. 2209 - Fixing Global Freeloading Act H.R. 6049 - Medical Supply Chain Security Act H.R. 6482 - Protecting Our Pharmaceutical Supply Chain from China Act of 2020 H.R. 6690 - Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6731 - Securing America's Pharmaceutical Supply Chain Act H.R. 6879 - Buy American Medical Supply Chain Act of 2020 H.R. 7492 - To designate all of Puerto Rico as an opportunity zone H.R. 7505 - American Innovation Act of 2020: Provisions related to manufacturing tax incentives H.R. 7574 - Strengthening America's Strategic National Stockpile Act of 2020 H.R. 7955 - 21st Century Buy American Act S. 3343 - Medical Supply Chain Security Act S. 3478 - To establish a commission to assess, evaluate, and address the dependence of the United States on medications, devices, and medical equipment from foreign countries S. 3537 - A bill to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in China, and for other purposes S. 3942 - Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act S. 3945 - A bill to amend the Internal Revenue Code of 1986 to provide incentives for relocating manufacturing of pharmaceuticals and medical supplies and devices to the United States H.R. 4710 - Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6393 - Strengthening America's Supply Chain and National Security Act H.R. 6930 - MADE in America Act of 2020 H.R. 8943 - Pandemic Supplies Production Act H.R. 8987 - Enhancing the Security of the U.S. Pharmaceutical Supply Chain Act of 2020 H.R. 8905 - Supply Chain Security and Pharmaceutical Authentication Act of 2020 S. 3635 - Protecting Our Pharmaceutical Supply Chain from China Act of 2020 S. 4175 - Pharmaceutical Supply Chain Defense and Enhancement Act S. 4194 - National Institute of Manufacturing Act Pricing and reimbursement policy issues Supply chain and China Task Force policy issues

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON New —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); Office of Management & Budget (OMB); SENATE; Commerce, Dept of (DOC); State, Dept of (DOS); White House Office; Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); U.S. Trade Representative (USTR)

Bills named: H.R. 6731 (116th), H.R. 8905 (116th), H.R. 6049 (116th), H.R. 7492 (116th), H.R. 6393 (116th), H.R. 7574 (116th), H.R. 2209 (116th), S. 3635 (116th), H.R. 4710 (116th), H.R. 6690 (116th), H.R. 6482 (116th), H.R. 6879 (116th), S. 4194 (116th), S. 3537 (116th), H.R. 8987 (116th), S. 3942 (116th), H.R. 6930 (116th), H.R. 8943 (116th), S. 3478 (116th), S. 4175 (116th), H.R. 7505 (116th), H.R. 7955 (116th), S. 3945 (116th), S. 3343 (116th)

Taxation/Internal Revenue Code TAX

OECD Digital Tax ACA Pharmaceutical Industry Fee Exclusions Orphan Drug Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Anti-Abuse Tax (BEAT) Tax Cuts & Jobs Act Implementation Innovation Box Tax Treaties Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (HR 748)(S. 3548) Pharmaceutical supply chain incentives U.S. Corporate Tax

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON New —

Contacted: SENATE; Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); White House Office; U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); State, Dept of (DOS); Food & Drug Administration (FDA); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 3548 (116th), H.R. 748 (116th)

Copyright/Patent/Trademark CPT

Biopharmaceutical Intellectual Property Data exclusivity Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO BPCIA Patents Inter Partes Review at PTO Biosimilars S 1416 - Affordable Prescriptions for Patients Act of 2019 H.R.465 - Prescription Drug Price Relief Act of 2019 H.R.938 - BLOCKING Act of 2019 H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.1046 - Medicare Negotiation and Competitive Licensing Act of 2019 Bayh-Dole Act Section 101 H.R.3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R.4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 S.1617 - Second Look at Drug Patents Act of 2019 HR 4712 - Fairness in Orphan Drug Exclusivity Act HR 4850 - Biologic Patent Transparency Act - Provisions related to prescription drug patent disclosures HR 5133 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Intellectual Property Issues in Response to coronavirus S.2387 - We Protect American Investment in Drugs Act of 2019 S.64 - Preserve Access to Affordable Generics & Biosimilars Act of 2019

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON New —

Contacted: U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); White House Office; U.S. Agency for International Development (USAID); State, Dept of (DOS); SENATE

Bills named: S. 64 (116th), S. 2387 (116th), H.R. 4398 (116th), H.R. 5133 (116th), H.R. 3991 (116th), H.R. 1046 (116th), S. 1617 (116th), H.R. 938 (116th), H.R. 4850 (116th), H.R. 465 (116th), H.R. 987 (116th), H.R. 4712 (116th)

Health Issues HCR

S.2543 - Prescription Drug Pricing Reduction Act of 2019 HR 1499: Protecting Consumer Access to Generic Drugs Act Cell, gene and radioligand therapies 340B Drug Discount Program Drug Importation Outcomes based Contracting/Value based arrangements Orphan Drugs Medicaid Payment Reform AMP Cap S 1895 - Lower Health Care Costs Act HR 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.478 - Safe and Affordable Drugs from Canada Act of 2019 H.R.2011 - Protecting Access to Biosimilars Act of 2019 H.R.2296 - FAIR Drug Pricing Act of 2019 S.61 - Safe and Affordable Drugs from Canada Act of 2019 S.1140 - Protecting Access to Biosimilars Act of 2019 S.1384 - Prescription Drug Rebate Reform Act of 2019 S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 S.1227 - Prescription Pricing for the People Act of 2019 H.R.447 - Affordable and Safe Prescription Drug Importation Act H.R.1922 - Restoring Access to Medication Act of 2019 H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes H.R.5304 - PBM Transparency in Prescription Drug Costs Act S.97 - Affordable and Safe Prescription Drug Importation Act S.657 - A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits Transparency policy issues Drug cost and pricing policy issues PDUFA, BSUFA, GDUFA Drug vial size policy issues Pharmaceutical supply chain H.R. 4710 - Pharmaceutical Independence Long-Term Readiness Reform Act S. 3635 - Protecting our Pharmaceutical Supply Chain from China Act of 2020 S. 3538 - Strengthening Americas Supply Chain and Medical Security Act H.R. 6431 - Made in America Emergency Preparedness Act HR 6080 - Prevent Drug Shortages Act S. 3432 - Securing Americas Medicine Cabinet Act of 2020 H.R. 6670 - Prescription for American Drug Independence Act of 2020 H.R. 6930 - MADE in America Act HR 4439 - Creating Hope Reauthorization Act Pharmaceutical quality COVID 19 H.R 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act H.R. 748 and S. 3548 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act) H.R. 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 S. 3370 - Coronavirus Vaccine Act CARES Act, Pub. L. 116-136 H.R. 6080 - Preventing Drug Shortages Act Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Drug shortages policy issues Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Diversity in Clinical Trials FY 2021 Labor-HHS Appropriations Cures 2.0 Energy and Commerce RFI Part B Home Infusion Notice of Benefit Payment Parameters (NBPP) Priority Review Voucher (PRV) H.R. 4400 - The Advancing Education on Biosimilars Act of 2019 Vaccines Executive Order 13948, Lowering Drug Prices by Putting America First (September 13, 2020) - Provisions on Part B and D, Most Favored Nation, and other issues Executive Order 13944, Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (August 6, 2020) Executive Order 13938, Increasing Drug Importation to Lower Prices for American Patients (July 24, 2020) Medicaid Generics Penalty fix HR 8337 - Continuing Appropriations Act, 2021 and Other Extensions Act H.R.2374 - Stop STALLING Act H.R. 5239 - Prescription Drug Price Reporting Act H.R. 6258 - Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 H.R. 6390 - To require the President to use authorities under the Defense Production Act of 1950 to require emergency production of medical equipment to address the COVID-19 outbreak H.R. 6410 - To direct the President to use authority under the Defense Production Act of 1950 to ensure an adequate supply equipment necessary for limiting the spread of COVID-19 H.R. 6395/S. 4049 - National Defense Authorization Act for Fiscal Year 2021 HHS PREP Act declaration relating to COVID-19 Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Expanded access policy issues FDA modernization policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues FDA mandatory recall authority policy issues COVID-19 policy issues Transparency Issues Policy Issue H.R. 2477 - Beneficiary Enrollment Notification and the Eligibility Simplification (BENES) Act of 2019 H.R. 6800 - Heroes Act

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON New —

Contacted: Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); SENATE; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); State, Dept of (DOS); Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); White House Office; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4439 (116th), H.R. 3772 (116th), S. 1384 (116th), S. 3370 (116th), S. 1391 (116th), H.R. 8337 (116th), H.R. 4710 (116th), S. 3538 (116th), H.R. 6800 (116th), H.R. 2374 (116th), H.R. 1499 (116th), H.R. 6258 (116th), H.R. 748 (116th), S. 657 (116th), H.R. 6390 (116th), H.R. 6670 (116th), H.R. 6410 (116th), H.R. 6930 (116th), S. 61 (116th), H.R. 5239 (116th), H.R. 4400 (116th), H.R. 2477 (116th), S. 1227 (116th), S. 97 (116th), H.R. 6074 (116th), H.R. 6201 (116th), H.R. 6080 (116th), H.R. 987 (116th), S. 3635 (116th), H.R. 5304 (116th), H.R. 6431 (116th), S. 3548 (116th), S. 1140 (116th), S. 3432 (116th), H.R. 6395 (116th), H.R. 1922 (116th), S. 2543 (116th), H.R. 2064 (116th), H.R. 447 (116th), H.R. 478 (116th), H.R. 2011 (116th), S. 4049 (116th), H.R. 2296 (116th)

Foreign Relations FOR

CFIUS Reform Foreign Agents Registration Act (FARA) Reform S.1762 - Foreign Agents Disclosure and Registration Enhancement Act of 2019

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON New —

Contacted: Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Office of Management & Budget (OMB); Commerce, Dept of (DOC); State, Dept of (DOS); U.S. Trade Representative (USTR); SENATE

Bills named: S. 1762 (116th)

Budget/Appropriations BUD

Certified Importer Program (CIP) Biosimilars Importation Drug Pricing Value of Medicine Fiscal year 2021 Appropriations H.R. 6395/S. 4049 - National Defense Authorization Act for Fiscal Year 2021 S. 4320 - Coronavirus Response Additional Supplemental Appropriations Act, 2020 S. 4775 - Delivering Immediate Relief to America's Families, Schools & Small Businesses Act S. 4800 - The Heroes Act CARES Act, Pub. L. 116-136 H.R. 133 - Consolidated Appropriations Act, 2021 H.R. 6800 - Heroes Act S. 4049 - NDAA H.R. 7614 - FY 2021 Labor-HHS Appropriations

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON New —

Contacted: Veterans Affairs, Dept of (VA); Commerce, Dept of (DOC); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; White House Office; State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 4049 (116th), H.R. 6395 (116th), S. 4320 (116th), H.R. 133 (116th), H.R. 7614 (116th), S. 4800 (116th), H.R. 6800 (116th), S. 4775 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.